How many "me-too" drugs is too many?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2011-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2011.152PMID 21325189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Copayment levels and medication adherence: less is more.

  2009cited by this paper
• Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

  2008cited by this paper
• Potential Savings From Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000

  2006cited by this paper
• Book Review

  2006cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Prescription drugs and managed care: can 'free-market détente' hold?

  2000cited by this paper
• HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY

  1998cited by this paper
• Medical decision making in situations that offer multiple alternatives.

  1995cited by this paper

• Network pharmacology to elucidate the role of phytotherapy in neurocognitive disorders.

  2025cites this paper
• The clinical trials puzzle: How network effects limit drug discovery

  2023cites this paper
• The Real Effects of Equity Markets on Innovation

  2022cites this paper
• Evolution of drug regulations and regulatory innovation for anticancer drugs in China

  2022cites this paper
• The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis

  2022cites this paper
• Study of knowledge, attitude, and practice of “me-too drugs” among the prescribers in a tertiary care hospital – A cross-sectional study

  2021cites this paper
• Evaluating Diuretics in Normal Care (EVIDENCE): a feasibility report of a pilot cluster randomised trial of prescribing policy in primary care to compare the effectiveness of thiazide-type diuretics in hypertension

  2021cites this paper
• Innovation crisis in the pharmaceutical industry? A survey

  2021cites this paper
• Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action

  2021cites this paper
• Pharmaceutical Simplification: Killing Two Birds with One Stone.

  2021cites this paper
• R&D-driven medical progress, health care costs, and the future of human longevity

  2021cites this paper
• Commercialization, Consent, and the Neural Device Industry

  2021cites this paper
• The Death of the Genus Claim

  2020cites this paper
• Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England

  2020cites this paper
• Evaluating Diuretics in Normal Care (EVIDENCE): protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension

  2020cites this paper
• The role of regulators in mitigating uncertainty within the Valley of Death

  2020cites this paper
• The proportion of North American cancer trials that evaluate novel targets

  2020cites this paper
• An Analysis of Follow‐On Development in New Drug Classes, January 1986–June 2018

  2019cites this paper
• Designing a “Solution-Focused” Governance Paradigm for Synthetic Biology: Toward Improved Risk Assessment and Creative Regulatory Design

  2019cites this paper
• The Price of Substitute Technologies.

  2019cites this paper
• Competition and price among brand-name drugs in the same class: A systematic review of the evidence

  2019cites this paper
• Solid and solution properties of the antimicrobial agent clofazimine

  2018cites this paper
• Contemporary Advances and Precincts of Biopharming as Drugs’ Production Systems

  2018cites this paper
• What Can Big Data on Academic Interest Reveal about a Drug? Reflections in Three Major US Databases.

  2018cites this paper
• Determinants of drug utilisation during childhood

  2018cites this paper
• The Effect of Opioid Use and Mental Illness on Chronic Disease Medication Adherence in Superutilizers

  2018cites this paper
• Sustainable health and degrowth: Health, health care and society beyond the growth paradigm

  2017cites this paper
• Sustainable health and degrowth: Health, health care and society beyond the growth paradigm

  2017cites this paper
• The Financialization of a Cure: A Political Economy of Biomedical Innovation, Pricing, and Public Health

  2017cites this paper
• A critical look at innovation profile and its relationship with pharmaceutical industry

  2017cites this paper
• Why There Is No Obligation to Participate in Clinical Research

  2017cites this paper
• Open innovation in early drug discovery: roadmaps and roadblocks.

  2016cites this paper
• An analysis of FDA-approved drugs for cardiovascular diseases.

  2016cites this paper
• Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties.

  2016cites this paper
• Genome-guided Investigation of Antibiotic Substances produced by Allosalinactinospora lopnorensis CA15-2T from Lop Nor region, China

  2016cites this paper
• Commentary on Current Trends in Rising Drug Costs and Reimbursement Below Cost.

  2016cites this paper
• Faster drug approval: challenges for safety

  2016cites this paper
• An Unusual Pigmented Lesion: What Is Your Diagnosis?

  2016cites this paper
• Pharmaceutical patenting and the transformation of American medical ethics

  2016cites this paper
• Competitive Development in Pharmacologic Classes: Market Entry and the Timing of Development

  2016cites this paper
• A history of drug development in four acts.

  2015cites this paper
• [Bioethical responsibilities of the health authority in health care and biomedical research].

  2015cites this paper
• Premium policy? Getting better value from the PBS

  2015cites this paper
• Regulators Should Better Leverage Effectiveness Standards to Enhance Drug Value

  2014cites this paper
• The Health Impact Fund: how might it work for novel anticoagulants in atrial fibrillation?

  2014cites this paper
• Review of Italian primary care paediatricians identifies 38 commonly prescribed drugs for children

  2014cites this paper
• Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden

  2014cites this paper
• Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries.

  2014cites this paper
• Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes

  2014cites this paper
• Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges

  2014cites this paper
• Entry time effects and follow-on drug competition

  2014cites this paper
• Deadly gaps in the patent system : an analysis of currentand alternative mechanisms for incentivising development of medical therapies.

  2014cites this paper
• Current Trends in Collaborative Drug Discovery and Strategies to De‐Risk Precompetitive Initiatives

  2014cites this paper
• Essays on Innovation, Competition and Regulation in the Pharmaceutical Industry

  2014cites this paper
• Market Withdrawals Era Of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings And

  2014cites this paper
• Patent Breadth versus Length: An Examination of the Pharmaceutical Industry

  2014cites this paper
• Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.

  2014cites this paper
• Non-inferiority cancer clinical trials: scope and purposes underlying their design.

  2013cites this paper
• Comparative Effectiveness Research/Health Technology Assessment (HTA) Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research

  2013cites this paper
• Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research.

  2013cites this paper
• An unusual pigmented lesion: what is your diagnosis?

  2013cites this paper
• Me-too drugs and me-too people.

  2013cites this paper
• Future Viable Models of Psychiatry Drug Discovery in Pharma

  2013cites this paper
• Increasing enrollment in drug trials: the need for greater transparency about the social value of research in recruitment efforts.

  2013cites this paper
• Sample Closet Medications Are Neither Novel Nor Useful

  2013cites this paper
• Challenging research on human subjects: justice and uncompensated harms

  2013cites this paper
• How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?

  2013cites this paper
• An early indicator of drug success: Top Journal Selectivity Index

  2013cites this paper
• The Role and Impact of Research Agendas on the Comparative‐Effectiveness Research Among Antihyperlipidemics

  2012cites this paper
• Top journals selectivity index and “me-too” drugs

  2012influential citation
• Raising the bar for market authorisation of new drugs

  2012cites this paper
• Availability of comparative efficacy data at the time of drug approval in the United States.

  2011cites this paper
• Evidence of comparative efficacy should have a formal role in European drug approvals

  2011cites this paper
• Pharmacy and Therapeutics Committees: Leadership Opportunities in Medication Safety for Medical Toxicologists

  2011cites this paper
• Evidence of Comparative Efficacy Should Have a Formal Role in European Drug Approvals Article (published Version) (refereed)

  year unknowncites this paper
• Non-inferiority Cancer Clinical Trials: Scope and Purposes Underlying Their Design Annals of Oncology

  year unknowncites this paper